Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy

Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy

(2015) Hayato Fujita et al.   NEOPLASIA

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

(2013) William Greenhalf et al.   JNCI-Journal of the National Cancer Institute

A Meta-Analysis of Gemcitabine Biomarkers in Patients With Pancreaticobiliary Cancers

(2013) Christina H. Wei et al.   PANCREAS

Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Advanced Cholangiocarcinoma Patients Treated With Gemcitabine-Based Adjuvant Chemotherapy After Surgical Resection

(2012) Hironori Kobayashi et al.   ANNALS OF SURGERY

Evolution of Surgical Treatment for Perihilar Cholangiocarcinoma

(2012) Masato Nagino et al.   ANNALS OF SURGERY

Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy

(2012) Sarah B. Fisher et al.   CANCER

Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma

(2012) Raphaël Maréchal et al.   GASTROENTEROLOGY

Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors

(2012) Yoshiaki Murakami et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection

(2012) Naoya Nakagawa et al.   SURGERY

RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: A meta-analysis

(2011) Weiyi Gong et al.   LUNG CANCER

Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma

(2010) Yoshiaki Murakami et al.   ANNALS OF SURGICAL ONCOLOGY

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

(2010) T Okusaka et al.   BRITISH JOURNAL OF CANCER

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer

(2010) Lars Petter Jordheim et al.   LANCET ONCOLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Gemcitabine Plus S-1 Chemotherapy Improves Survival After Aggressive Surgical Resection for Advanced Biliary Carcinoma

(2009) Yoshiaki Murakami et al.   ANNALS OF SURGERY

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

(2009) H Akita et al.   ONCOGENE

Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer

(2008) James J. Farrell et al.   GASTROENTEROLOGY